Their lead drug failed both main goals in key study, but Or­p­hazyme plans to pitch sub­group analy­ses to reg­u­la­tors

Or­p­hazyme at­tempt­ed on Wednes­day to en­thuse in­vestors about the re­sults of a Phase II/III study test­ing their lead drug, ari­mo­clo­mol, in pa­tients with a rare …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER